Isala, Zwolle, The Netherlands.
Isala, Zwolle, The Netherlands.
Int J Cardiol. 2018 Aug 15;265:12-17. doi: 10.1016/j.ijcard.2018.04.120. Epub 2018 Apr 25.
The no-reflow phenomenon is a serious complication after primary percutaneous coronary intervention (PCI) for ST-elevation Myocardial Infarction (STEMI). Coronary artery ectasia (CAE) may increase the risk of no-reflow, however, only limited data is available on the potential impact of CAE. The aim of this study was to determine the potential association between CAE and no-reflow after primary PCI.
A case control study was performed based on a prospective cohort of STEMI patients from January 2000 to December 2011. All patients with TIMI 0-1 flow post primary PCI, in the absence of dissection, thrombus, spasm or high-grade residual stenosis, were considered as no-reflow case. Control subjects were two consecutive STEMI patients after each case, with TIMI flow ≥2 after primary PCI. CAE was defined as dilatation of an arterial segment to a diameter at least 1.5 times that of the adjacent normal coronary artery.
In the no-reflow group, frequency of CAE was significantly higher (33.8% vs 3.9%, p < 0.001) compared to the control group. Baseline variables were comparable between patients with and without CAE. Patients with CAE had more often TIMI 0-1 flow pre-PCI (91% vs 71% p = 0.03), less often anterior STEMI (3% vs 37%, p < 0.001) and underwent significantly less often a PCI with stenting (47% vs 74%, p = 0.003). After multivariate analysis, CAE remained a strong and independent predictor of no-reflow (OR 13.9, CI 4.7-41.2, p < 0.001).
CAE is a strong and independent predictor of no-reflow after primary PCI for STEMI. Future studies should assess optimal treatment.
无复流现象是 ST 段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入治疗(PCI)后的严重并发症。冠状动脉扩张(CAE)可能会增加无复流的风险,但目前关于 CAE 潜在影响的资料有限。本研究旨在确定 CAE 与经皮冠状动脉介入治疗后无复流之间的潜在关联。
基于 2000 年 1 月至 2011 年 12 月的 STEMI 患者前瞻性队列,进行病例对照研究。所有经皮冠状动脉介入治疗后 TIMI 血流 0-1 级、无夹层、血栓、痉挛或高度残留狭窄的患者均被认为是无复流病例。对照组为每个病例后的两个连续 STEMI 患者,经皮冠状动脉介入治疗后 TIMI 血流≥2 级。CAE 定义为动脉节段扩张至至少是相邻正常冠状动脉直径的 1.5 倍。
无复流组 CAE 的发生率明显高于对照组(33.8% vs 3.9%,p<0.001)。CAE 患者与无 CAE 患者的基线变量无差异。CAE 患者 PCI 术前 TIMI 血流 0-1 级更多(91% vs 71%,p=0.03),前壁 STEMI 较少(3% vs 37%,p<0.001),PCI 支架置入术较少(47% vs 74%,p=0.003)。多变量分析后,CAE 仍然是无复流的一个强有力的独立预测因素(OR 13.9,CI 4.7-41.2,p<0.001)。
CAE 是 STEMI 患者经皮冠状动脉介入治疗后无复流的一个强有力的独立预测因素。未来的研究应评估最佳治疗方法。